Tags

Type your tag names separated by a space and hit enter

How can we improve the treatment of bone metastases further?
Curr Opin Oncol. 1998 Aug; 10 Suppl 1:S7-13.CO

Abstract

Bone is one of the most frequent organs to be affected by metastatic cancer and causes more morbidity than any other metastatic site. Bisphosphonate treatment provides an organ-specific treatment which is relevant to most if not all tumour types involving bone. Bisphosphonates, particularly the potent agent pamidronate (Aredia), will relieve metastatic bone pain with a consequent improvement in quality of life in approximately 50% of patients. Long-term bisphosphonate treatment clearly reduces skeletal morbidity rates in multiple myeloma and breast cancer.

Authors+Show Affiliations

YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9801853

Citation

Coleman, R E.. "How Can We Improve the Treatment of Bone Metastases Further?" Current Opinion in Oncology, vol. 10 Suppl 1, 1998, pp. S7-13.
Coleman RE. How can we improve the treatment of bone metastases further? Curr Opin Oncol. 1998;10 Suppl 1:S7-13.
Coleman, R. E. (1998). How can we improve the treatment of bone metastases further? Current Opinion in Oncology, 10 Suppl 1, S7-13.
Coleman RE. How Can We Improve the Treatment of Bone Metastases Further. Curr Opin Oncol. 1998;10 Suppl 1:S7-13. PubMed PMID: 9801853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How can we improve the treatment of bone metastases further? A1 - Coleman,R E, PY - 1998/11/5/pubmed PY - 1998/11/5/medline PY - 1998/11/5/entrez SP - S7 EP - 13 JF - Current opinion in oncology JO - Curr Opin Oncol VL - 10 Suppl 1 N2 - Bone is one of the most frequent organs to be affected by metastatic cancer and causes more morbidity than any other metastatic site. Bisphosphonate treatment provides an organ-specific treatment which is relevant to most if not all tumour types involving bone. Bisphosphonates, particularly the potent agent pamidronate (Aredia), will relieve metastatic bone pain with a consequent improvement in quality of life in approximately 50% of patients. Long-term bisphosphonate treatment clearly reduces skeletal morbidity rates in multiple myeloma and breast cancer. SN - 1040-8746 UR - https://www.unboundmedicine.com/medline/citation/9801853/How_can_we_improve_the_treatment_of_bone_metastases_further L2 - https://medlineplus.gov/bonecancer.html DB - PRIME DP - Unbound Medicine ER -